LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Post-Mkt 03-11 17:13:23 EDT

1.45

+0.04

+2.84%

盘后1.45

+0.000.00%

17:03 EDT

High1.46	Low1.37	Vol851.11K
Open1.40	D1 Closing1.41	Amplitude6.03%
Mkt Cap189.84M	Tradable Cap118.38M	Total Shares130.92M
T/O1.21M	T/O Rate1.04%	Tradable Shares81.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":1.45,"timestamp":1773259200000,"preClose":1.41,"halted":0,"volume":851109,"hourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.45,"latestTime":"17:03 EDT","volume":3226,"amount":4677.7,"timestamp":1773263039238,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.028368794326241162,"floatShares":81639200,"shares":130924686,"eps":-0.786597,"marketStatus":"Post-Mkt","change":0.04,"latestTime":"03-11 17:13:23 EDT","open":1.4,"high":1.455,"low":1.37,"amount":1214429.3885891999,"amplitude":0.060284,"askPrice":1.47,"askSize":100,"bidPrice":1.3,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.786597,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773273600000},"marketStatusCode":4,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":1.41,"preHourTrading":{"tag":"盘前","latestPrice":1.4,"preClose":1.41,"latestTime":"09:29 EDT","volume":6665,"amount":9379.3325805,"timestamp":1773235779240,"change":-0.01,"changeRate":-0.007092,"amplitude":0.021277},"postHourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.45,"latestTime":"17:03 EDT","volume":3226,"amount":4677.7,"timestamp":1773263039238,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.433894},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2608336480","title":"Press Release: PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2608336480","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608336480?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:01","pubTimestamp":1770210060,"startTime":"0","endTime":"0","summary":"Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination. Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting. Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang. The Company used the proceeds from these financings, consisting of a $22.3 million cash payment and the $15 million long-term senior secured note, to redeem all outstanding shares of its Series C Convertible Preferred Stock, and fully retire its outstanding convertible debt. The remaining $7.7 million in net cash proceeds will be available for general working capital purposes. In total, assuming exercise of the associated warrants upon publication of a positive EsoGuard LCD and conversion of the Series","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4082","BK4232","LUCD","R","PAVM"],"gpt_icon":0},{"id":"2605403839","title":"Individual investors among Lucid Diagnostics Inc.'s (NASDAQ:LUCD) largest stockholders and were hit after last week's 14% price drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2605403839","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605403839?lang=en_us&edition=fundamental","pubTime":"2026-01-23 18:39","pubTimestamp":1769164754,"startTime":"0","endTime":"0","summary":"Key Insights Lucid Diagnostics' significant individual investors ownership suggests that the key decisions are...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lucd/lucid-diagnostics/news/individual-investors-among-lucid-diagnostics-incs-nasdaqlucd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lucd/lucid-diagnostics/news/individual-investors-among-lucid-diagnostics-incs-nasdaqlucd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QID","PSQ","QQQJ","BK4082","NVIW.SI","LCID","TSYW.SI","GPIQ","NQmain","BK4555",".IXIC","MNQmain","USJW.SI","BK4551","BK4596","USAW.SI","QQQE","LUCD","QQQY","QYLG","QYLD","TQQQ","JEPQ","QLD","BK4099","SQQQ"],"gpt_icon":1},{"id":"2605497182","title":"What's Going On With PAVmed Shares Thursday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605497182","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605497182?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:23","pubTimestamp":1769091780,"startTime":"0","endTime":"0","summary":"PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diagnostics secured a contract","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/22/benzingaai2023-modern-computer-screen-wi.png?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/22/benzingaai2023-modern-computer-screen-wi.png?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/50067878/whats-going-on-with-pavmed-shares-thursday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/50067878/whats-going-on-with-pavmed-shares-thursday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SMA","BK4082","LUCD","BK4217","PAVM"],"gpt_icon":0},{"id":"2605867214","title":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605867214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605867214?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:49","pubTimestamp":1769010597,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers CompaniesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM11M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRV","SLB","BKR","CNX","F","ROCK","AMBQ","IE00B29SXL02.USD","BK4141","ALB","JNJ","LU2430703095.HKD","AVR","SCHW","PLD","IE00BBT3K403.USD","KHC","TFC","NATH","BK4533","LNG","OCGN","BIOA","HL","LU0154245673.USD","WMB","GM","LSTA","DXC","LUCD","LU0985481810.HKD","LXRX","LBRT","NEM","TDY","HAL","IE00B775SV38.USD","BK4534","EXE","OCUL","CBIO","CDE","UAL","NNE","INTC","ALGS","LPTH"],"gpt_icon":1},{"id":"2605483858","title":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605483858?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:25","pubTimestamp":1769005524,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s FamousEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL6N3YM0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861165.SGD","LU0130103400.USD","IE00BLSP4452.SGD","FCX","PLD","HL","JNJ","BK4145","LXRX","LU0417517546.SGD","TDY","OCUL","ARM","LU2463526074.USD","TEL","LU2362540622.SGD","BKR","LU2272731600.USD","NEM","RIO.UK","PAVM","RIO.AU","LBRT","KHC","LU1023059063.AUD","LU0347712357.USD","LU2272731782.SGD","SCHW","ALB","SG9999002224.SGD","TFC","IE0004091025.USD","LPTH","BIOA","HAL","LU1066051811.HKD","UAL","ROCK","AVR","LU0079474960.USD","CDE","LUCD","NATH","TRV","BHP.AU","SLB","CBIO","SG9999002232.USD","NFLX"],"gpt_icon":0},{"id":"2605089488","title":"PAVmed Subsidiary Lucid Diagnostics Wins US Department of Veterans Affairs Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2605089488","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605089488?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:22","pubTimestamp":1769005336,"startTime":"0","endTime":"0","summary":"PAVmed  subsidiary Lucid Diagnostics  said Wednesday it won a contract from the US Department of Veterans Affairs for its EsoGuard esophageal DNA test for esophageal precancer testing.Financial terms of the contract were not disclosed.The contract includes pre-negotiated pricing for the test that matches the established Medicare payment rate determined by the Centers for Medicare & Medicaid Services, enabling access through a single, national procurement framework, the company said.Shares of PAVmed and Lucid Diagnostics were up 180% and 29% respectively in recent premarket activity Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4555","PAVM","BK4596","BK4551","BK4082","LUCD","LCID","BK4099"],"gpt_icon":0},{"id":"2605310001","title":"Why Are PAVmed (PAVM) & Lucid Diagnostics (LUCD) Stocks Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605310001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605310001?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:49","pubTimestamp":1769003351,"startTime":"0","endTime":"0","summary":"PAVmed stock gained on Wednesday after the company announced a contract with the VA.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-are-pavmed-pavm-lucid-diagnostics-lucd-stocks-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-are-pavmed-pavm-lucid-diagnostics-lucd-stocks-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4099","BK4555","LUCD","BK4596","BK4082","BK4551","PAVM","LCID"],"gpt_icon":0},{"id":"2605107708","title":"BUZZ-Lucid Diagnostics rises after winning VA contract for cancer test","url":"https://stock-news.laohu8.com/highlight/detail?id=2605107708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605107708?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:29","pubTimestamp":1769002199,"startTime":"0","endTime":"0","summary":"BUZZ-Lucid Diagnostics rises after winningVA contract for cancer test** Shares of cancertest developer Lucid Diagnostics LUCD.O rise 3.31% to $1.25 premarket** Co says it has secured a U.S. Veterans Affairs contract for EsoGuard, its test that checks for DNA changes linked to early esophageal cancer** Esophageal cancer often begins as damage from longterm heartburn and EsoGuard uses a quick office procedure to collect cells and screen for these changes, per LUCD** Says VA hospitals and clinics nationwide can now buy the test at Medicarematched pricing, giving more than 9 million people access to early esophageal cancer screening ** LUCD gained ~33% in 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM1AU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUCD","PAVM"],"gpt_icon":0},{"id":"2605102444","title":"Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for Esoguard®","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605102444?lang=en_us&edition=fundamental","pubTime":"2026-01-21 21:01","pubTimestamp":1769000506,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YM0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUCD","PAVM","BK4082"],"gpt_icon":0},{"id":"2595907137","title":"BRIEF-PAVmed Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2595907137","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595907137?lang=en_us&edition=fundamental","pubTime":"2025-12-30 22:06","pubTimestamp":1767103584,"startTime":"0","endTime":"0","summary":"BRIEF-PAVmed Announces Reverse Stock SplitDec 30 (Reuters) - PAVmed PAVM.O:PAVMED ANNOUNCES REVERSE STOCK SPLITPAVMED INC: TO CONDUCT 1-FOR-30 REVERSE STOCK SPLIT OF ITS COMMON STOCKPAVMED INC - REVER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nTUA6VYH1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","PAVM","LUCD"],"gpt_icon":0},{"id":"2589884858","title":"Lucid Diagnostics Files for Mixed Shelf of up to $175 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589884858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589884858?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:04","pubTimestamp":1764972247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUCD","BK4082"],"gpt_icon":0},{"id":"2584944800","title":"Lucid Diagnostics (LUCD) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944800","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944800?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:26","pubTimestamp":1763558801,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Lucid Diagnostics, with a price target of $3.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lucid-diagnostics-lucd-receives-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lucid-diagnostics-lucd-receives-a-buy-from-cantor-fitzgerald-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LCID","BK4596","BK4099","BK4551","BK4555","LUCD"],"gpt_icon":0},{"id":"2583462534","title":"Lucid Diagnostics Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583462534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583462534?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:39","pubTimestamp":1763008780,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc. ( ($LUCD) ) has released its Q3 earnings. Here is a breakdown of the information Lucid Diagnostics Inc. presented to its inv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LUCD","BK4082","BK4555","LCID","BK4551","BK4596","BK4099"],"gpt_icon":0},{"id":"2582372579","title":"Lucid Diagnostics Gains Medicare Support for EsoGuard","url":"https://stock-news.laohu8.com/highlight/detail?id=2582372579","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582372579?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:51","pubTimestamp":1762955460,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has issued an update. Lucid Diagnostics reported its third-quarter 2025 financial results, highlighting the processin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-gains-medicare-support-for-esoguard?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-gains-medicare-support-for-esoguard?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4555","LCID","LUCD","BK4099","BK4596","BK4082","BK4551"],"gpt_icon":0},{"id":"2573952129","title":"Lucid Diagnostics Inc. Files Initial Beneficial Ownership Statement for Director John R. Palumbo","url":"https://stock-news.laohu8.com/highlight/detail?id=2573952129","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573952129?lang=en_us&edition=fundamental","pubTime":"2025-10-08 04:46","pubTimestamp":1759869976,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing discloses that John R. Palumbo, serving as a director of the company, holds a beneficial ownership in Lucid Diagnostics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL5v6Wc3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"gpt_icon":0},{"id":"2570923580","title":"Press Release: Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2570923580","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570923580?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:01","pubTimestamp":1758801660,"startTime":"0","endTime":"0","summary":"Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors. NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  , a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025.\"John is a highly accomplished executive whose 40 years of healthcare leadership experience spans early-stage ventures, growth-stage companies, and Fortune 100 corporations,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"His vast experience and deep expertise--which includes guiding early-stage companies through commercial growth--and vast network will be of great value as we approach transformational commercial milestones.\". Prior to that, he held senior executive roles at AmerisourceBergen Corporation , where he led the Provider business u","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4585","PAVM","BK4099","BK4232","BK4137","R","HCSG","LCID","XLV","XBI","NQmain","BK4596","BK4551","BK4022","LUCD","BK4588","BK4555","LABU","BK4581"],"gpt_icon":0},{"id":"2567102132","title":"Press Release: Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2567102132","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567102132?lang=en_us&edition=fundamental","pubTime":"2025-09-16 20:01","pubTimestamp":1758024060,"startTime":"0","endTime":"0","summary":"Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones--including Medicare coverage for EsoGuard--and to accelerate commercial coverage expansion. NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  , a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years of strategic and operational experience across market access, reimbursement, and government affairs. She will oversee Lucid's rapidly expanding market access and reimbursement activities, focused on payor engagement and securing broad insurance coverage and patient access to its EsoGuard Esophageal DNA Test.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4022","BK4099","R","BK4596","LUCD","BK4082","BK4232","PAVM","LCID","BK4551"],"gpt_icon":0},{"id":"2566464989","title":"Analysts Conflicted on These Healthcare Names: Lucid Diagnostics (LUCD) and Sanofi (OtherSNYNF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2566464989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566464989?lang=en_us&edition=fundamental","pubTime":"2025-09-12 09:40","pubTimestamp":1757641211,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lucid Diagnostics (LUCD – Research Report) and Sanofi (SNYNF – Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-lucid-diagnostics-lucd-and-sanofi-othersnynf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-lucid-diagnostics-lucd-and-sanofi-othersnynf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCID","BK4555","SNYNF","BK4099","LUCD","BK4596","HCSG","BK4137","BK4551","BK4007","BK4082"],"gpt_icon":0},{"id":"2566999025","title":"Lucid Diagnostics Closes Roughly $26.9 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2566999025","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566999025?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:53","pubTimestamp":1757598832,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics  said Thursday it closed an underwritten public offering of around 28.8 million common shares, including about 3.8 million shares issued under the full exercise of the overallotment option.The company said it expects total net proceeds to be around $26.9 million, which its intends to use for working capital and general corporate purposes.Price: 1.03, Change: +0.01, Percent Change: +0.98","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4596","BK4555","LUCD","BK4082","BK4099"],"gpt_icon":1},{"id":"2566999325","title":"Lucid Diagnostics Inc. Files Prospectus Supplement for Common Stock Offering, Raising Approximately $26.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2566999325","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566999325?lang=en_us&edition=fundamental","pubTime":"2025-09-11 21:28","pubTimestamp":1757597298,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc., a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., has announced the closing of an underwritten public offering of 28,750,000 shares of its common stock at a price of $1.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 3,750,000 shares. The offering is expected to yield net proceeds of approximately $26.9 million after expenses. The company plans to utilize these funds for working capital and general corporate purposes. Canaccord Genuity LLC and BTIG, LLC served as joint bookrunners, with Maxim Group LLC acting as co-manager. The securities were offered under a shelf registration statement declared effective by the SEC on December 6, 2022. The prospectus supplement and accompanying base prospectus were filed with the SEC on September 10, 2025. Copies of the prospectus are available from Canaccord Genuity LLC and BTIG, LLC.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL59BNwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","BK4082","PAVM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":-0.0276},{"period":"1month","weight":0.1557},{"period":"3month","weight":0.2368},{"period":"6month","weight":0.3178},{"period":"1year","weight":0.1849},{"period":"ytd","weight":0.2936}],"compareEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0195},{"period":"3month","weight":-0.0151},{"period":"6month","weight":0.0297},{"period":"1year","weight":0.208},{"period":"ytd","weight":-0.007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.035074},{"month":2,"riseRate":0.8,"avgChangeRate":0.165426},{"month":3,"riseRate":0.4,"avgChangeRate":-0.085563},{"month":4,"riseRate":0.5,"avgChangeRate":-0.092654},{"month":5,"riseRate":0.5,"avgChangeRate":0.04431},{"month":6,"riseRate":0.25,"avgChangeRate":-0.075357},{"month":7,"riseRate":0.5,"avgChangeRate":0.031793},{"month":8,"riseRate":0.75,"avgChangeRate":0.032951},{"month":9,"riseRate":0.25,"avgChangeRate":-0.178841},{"month":10,"riseRate":1,"avgChangeRate":0.186111},{"month":11,"riseRate":0.4,"avgChangeRate":-0.040647},{"month":12,"riseRate":0.2,"avgChangeRate":-0.154424}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction